Advertisement

Pen and Autoinjector Drug Delivery Devices

  • Ian Thompson
  • Jakob Lange
Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 6)

Abstract

Pens and autoinjectors are mainly used for the subcutaneous delivery of biopharmaceuticals, primarily for self-administration by the patient. The ability to self-inject has been the core driver for their development and made them such an important part of the world of drug delivery devices for more than 25 years. With the worldwide increase in diabetes as well as the trend towards biological drugs which cannot be administered orally, their importance continues to grow.

This chapter provides an overview of the different types of injection devices as well as what the development of such a device entails. Firstly, the landscape of injection devices is presented including a brief review of the different primary containers around which the devices are designed. The different types of pens and autoinjectors are described in some detail before reviewing the development process. The development sections outline the applicable regulatory requirements, provide examples of useful development tools, and then describe the different steps involved in injection device development and industrialization.

Keywords

Injection Molding Injection Device Prefilled Syringe Sumatriptan Succinate Human Factor Engineering 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. ASTM International (2010) Standard practice for heat aging of plastics without load, ASTM D3045-92Google Scholar
  2. Devonshire V, Arbizu T, Borre B, Lang M, Lugaresi A, Singer B, Verdun di Cantogno E, Cornelisse P (2010) Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multi-centre, Phase IIIb study. BMC Neurol 10(28). Available from http://www.biomedcentral.com/1471-2377/10/28
  3. Dumas H, Panayiotopoulos P, Parker D, Pongpairochana V (2006) Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord 6(5). Available from http://www.biomedcentral.com/1472-6823-6-5
  4. Food and Drug Administration (1997) Design control guidance for medical device manufacturers, 11 March 1997Google Scholar
  5. FDA (2000) Guidance for industry and FDA premarket and design control reviewers. Medical device use-safety: incorporating human factors engineering into risk management, identifying, understanding, and addressing use-related hazards, 18 July 2000Google Scholar
  6. French DL, Collins JJ (2010) Advances in parenteral injection devices and aids. In: Pharmaceutical dosage forms, parenteral medications, Regulations, validation and the future, 3rd edn. Informa Healthcare 3:71–75. http://informahealthcare.com/doi/abs/10.3109/9781420086485.005
  7. Guerlain S, Hugine A, Wang L (2010) A comparison of 4 epinephrine autoinjector delivery systems: usability and patient preference. Ann Allergy Asthma Immunol 104(2):172–177PubMedCrossRefGoogle Scholar
  8. Hey-Hadavi J, Pleil A, Deeb LC, Fuqua JS, Silverman LA, Reiner B, Newfield R, Raijicic N, Wajnrajch MP, Cara JF (2010) Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: a multi-center, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads. Clin Ther 32(12):2036–2047PubMedCrossRefGoogle Scholar
  9. International Standards Organisation (2000) Pen-injectors for medical use—Part 3: finished cartridges—requirements and test methods, ISO 11608-3:2000Google Scholar
  10. International Standards Organisation (2003) Medical devices—quality management systems—requirements for regulatory purposes, 2nd edn. ISO 13485:2003, 15 July 2003Google Scholar
  11. International Standards Organisation (2007) Medical devices—application of usability engineering to medical devices. ISO 62366:2007, October 2007Google Scholar
  12. International Standards Organisation (2010) Needle-based injection systems for medical use—requirements and test methods—Part 1: needle-based injection systems, 2nd edn. ISO 11608-1:2010. Draft for comments, November 2010Google Scholar
  13. Jorgensen JO, Mooller J, Jensen FS, Joorgensen JT, Christiansen JS (1989) Growth hormone administration by means of an injection pen. Pharmacol Toxicol 65(2):96–99PubMedCrossRefGoogle Scholar
  14. Pearson TL (2010) Practical aspects of insulin pen devices. J Diabetes Sci Technol 4(3):522–531PubMedGoogle Scholar
  15. Perfetti R (2010) Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and evaluation of inpatient insulin pen use. Diabetes Technol Ther 12(S1):S-79–S-85CrossRefGoogle Scholar
  16. Rex J, Jensen KH, Lawton SA (2006) A review of 20 years’ experience with the NovoPen family of insulin injection devices. Clin Drug Investig 26(7):367–401PubMedCrossRefGoogle Scholar
  17. Selam J-L (2010) Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 4(3):505–513PubMedGoogle Scholar
  18. Shah SG, Robinson I, AlShawi S (2009) Developing medical device technologies from users’ perspectives: a theoretical framework for involving users in the development process. Int J Technol Assess Health Care 25(4):514–521PubMedCrossRefGoogle Scholar
  19. Thompson I (2006) Market trends: self-injection devices. In: Drug delivery. A supplement to scrip world pharmaceutical news in conjunction with drug delivery partnerships & target world drug delivery news. Informa Healthcare, November 2006, pp 35–36Google Scholar
  20. Toraishi K, Yuizono Y, Nakamura N, Kato S, Aoki T, Ashida K, Sako Y (2005) Force requirements and insulin delivery profiles of four injection devices. Diabetes Technol Ther 7(4):629–635PubMedCrossRefGoogle Scholar
  21. US FDA (1996) US Code of Federal Regulations, Title 21, Chapter I, Subchapter H, Part 820—Quality System Regulation. US FDA, 7 Oct 1996. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=820

Copyright information

© American Association of Pharmaceutical Scientists 2013

Authors and Affiliations

  1. 1.Ypsomed AGBurgdorfSwitzerland

Personalised recommendations